Business
Bionano provides genome analysis solutions including optical genome mapping, nucleic acid extraction and purification systems, diagnostic services, and software.
Bionano is a genome-analysis platform company with FY2025 revenue down 7.4%, burn sharply improved, and an Altman distress signal.
The read at a glance✓ Audited against SEC data
- Business mix — Genome analysis solutionsNote
- Revenue — $28.5M, -7.4%Watch
- Gross margin — 46.3%, +4502 bpsOK
- FCF — -$16.3MWatch
- Loss — Net loss narrowed 76.4%OK
- Insiders — 0 purchases / 0 salesNote
- Accounting — Altman distress; Beneish clean; EQ 51.9Watch
Where the revenue comes from
Fiscal 2025, as Bionano Genomics, Inc. reports it. History and quarterly detail are in the app.
- Product$26.7M
- Consumable Revenue$14.0M
- Software Revenue$6.4M
- Instrument Revenue$6.4M
- Product And Service Other$1.8M
Leadership changes
From Bionano Genomics, Inc.'s own filings, the day they're filed.
- Alka Chaubey · Chief Medical Officer · departureeff. 2026-07-05
- Kristiina Vuori · Directors · appointmenteff. 2025-06-10
- R. Erik Holmlin · principal financial officer · appointmenteff. 2024-09-18
Latest filings
- 10-Q · Quarterly report2026-08-10
- 8-K · Company announcement2026-08-10
- 8-K · Company announcement2026-06-24
- 8-K · Company announcement2026-06-05
- 8-K · Company announcement2026-05-28
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Bionano Genomics, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.